Cellular genes regulated by hiv-1 infection and methods of use thereof -> Monitor Keywords

Site News |

Monitor Keywords |

Monitor Archive |

Organizer |

Account Info |

11/27/08 - USPTO Class 514 | 1 views | #20080293663 | Prev - Next | About this Page

Cellular genes regulated by hiv-1 infection and methods of use thereof

Title: Cellular genes regulated by hiv-1 infection and methods of use thereof

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20080293663, Cellular genes regulated by hiv-1 infection and methods of use thereof.

1-

30. (canceled)

31. A method for inducing apoptosis in a target cell comprising contacting the cell with a therapeutically effective amount of at least one agent capable of inhibiting HIV-Associated Life Preserver (HALP) activity, thereby inducing apoptosis.

32. The method as claimed in claim 31, wherein said agent is an antisense oligonucleotide or a small interfering double stranded RNA (siRNA) molecule.

33. The method as claimed in claim 31, wherein said target cell is infected by a retrovirus.

34. The method as claimed in claim 33, wherein said retrovirus is human immunodeficiency virus 1 (HIV-1).

35. The method as claimed in claim 32, wherein said target cell is transformed with a recombinant expression vector for expressing the antisense oligonucleotide or the siRNA molecule.

36. The method of claim 31, wherein said agent is administered to said target cell in combination with at least one anti-HIV agent.

37. The method of claim 36, wherein said anti-HIV agent is selected from the group consisting of protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, and fusion inhibitors.

38. The method of claim 31, wherein said agent is administered to said target cell in combination with at least one anti-HIV vaccine.

39. A method for decreasing the number of infected viable cells in a population of cells comprising contacting said population of cells with a therapeutically effective amount of at least one agent capable of inhibiting HIV-Associated Life Preserver (HALP) activity, thereby decreasing the number of infected viable cells in a population of cells.

40. The method as claimed in claim 39, wherein said agent is an antisense oligonucleotide or a small interfering double stranded RNA (siRNA) molecule.

41. The method as claimed in claim 39, wherein said target cell is infected by a retrovirus.

42. The method as claimed in claim 41, wherein said retrovirus is human immunodeficiency virus 1 (HIV-1).

43. The method as claimed in claim 40, wherein said target cell is transformed with a recombinant expression vector for expressing the antisense oligonucleotide or the siRNA molecule.

44. The method of claim 39, wherein said agent is administered to said target cell in combination with at least one anti-HIV agent.

45. The method of claim 44, wherein said anti-HIV agent is selected from the group consisting of protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, and fusion inhibitors.

46. The method of claim 39, wherein said agent is administered to said target cell in combination with at least one anti-HIV vaccine.

47. A method for treating a patient infected with the human immunodeficiency virus comprising administering to said patient at least one agent capable of inhibiting HIV-Associated Life Preserver (HALP) activity in a biologically compatible medium.

48. The method as claimed in claim 47, wherein said agent is an antisense oligonucleotide or a small interfering double stranded RNA (siRNA) molecule.

49. The method of claim 47, wherein said agent is administered to said target cell in combination with at least one anti-HIV agent.

50. The method of claim 49, wherein said anti-HIV agent is selected from the group consisting of protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, and fusion inhibitors.

51. The method of claim 48, wherein said antisense oligonucleotide or siRNA molecule are administered to said patient by administering to said patient a recombinant expression vector encoding said antisense oligonucleotide or siRNA molecule.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Cellular genes regulated by hiv-1 infection and methods of use thereof patent application.

Patent Applications in related categories:

20090291906 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment ...

20090291907 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment ...

###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like Cellular genes regulated by hiv-1 infection and methods of use thereof or other areas of interest.
###

Previous Patent Application:
Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
Next Patent Application:
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
Industry Class:
Drug, bio-affecting and body treating compositions

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the Cellular genes regulated by hiv-1 infection and methods of use thereof patent info.
IP-related news and info

Results in 0.05276 seconds

Other interesting Feshpatents.com categories:
Novartis , Pfizer , Philips , Polaroid , Procter & Gamble , 174

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO